The molecular subtyping of EEC, which includes POLE-ultramutated, MMR-deficient, p53-mutant, and no specific molecular profile (NSMP), has provided significant insights into the pathogenesis and potential therapeutic targets for these tumors (4). This evidence concerns the gene MRC1 and exstrophy-epispadias complex.